Have core biopsy or other minor surgical procedures within 7 days prior to the first dose of bevacizumab
Major surgical procedure or significant traumatic injury within 4 weeks prior to randomization and must have fully recovered from any such procedure or injury; planned surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months. Note: the following are not considered to be major procedures and are permitted up to 7 days before randomization: Thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, and imaging-guided biopsy for diagnostic purposes
Major surgery within 4 weeks of study entry; minor surgical procedures (e.g., port insertion) are not excluded, but sufficient time should have passed for wound healing (as determined by the treating investigator)
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: Major surgical procedure, or significant traumatic injury within 28 days of registration or incompletely healed surgical wounds are exclusions; minor surgical procedures such as placement of central venous device (excluding peripherally inserted central catheter [PICC] line) are allowed 7 days prior to enrollment to the study
Minor surgical procedures within 7 days of baseline, or not yet recovered from prior surgery.
Major surgical procedures ?14 days of beginning study drug, or minor surgical procedures ?7 days, or has not recovered from major side effects. No waiting required following port-a-cath placement.
Major surgical procedures < 28 days from beginning study treatment
Major surgical procedures =< 28 days of beginning study treatment, or minor surgical procedures (including ventriculoperitoneal [VP] shunt placement or stereotactic biopsy of the tumor) =< 7 days; no waiting period required following port-a-cath or other central venous access placement
Major surgical procedures =< 28 days of beginning study treatment, or minor surgical procedures =< 7 days; no waiting period required following port-a-cath or other central venous access placement
Patients who have had minor surgical procedures (with the exception of the placement of porta cath or other central venous access) within 7 days prior to registration
Major surgery within 14 days before enrollment; biopsies and line placement procedures are not exclusion criteria
Major surgical procedures ?28 days of beginning study treatment or minor surgical procedures ?7 days. No waiting is required following port-a-cath placement.
Major surgery within 28 days prior to the first drug administration (minimally invasive procedures such as diagnostic biopsies are permitted)
Port-a-cath placement: no waiting is required
Minor surgical procedures (as defined by the Investigator): 7 postoperative days
Major surgery within 4 weeks of first dose of study medications. Minor procedures (e.g. port placement, endoscopy with intervention) within 2 weeks of first dose of study medications are allowed
Major surgery within 6 weeks of first dose of study medications; minor procedures (e.g. port placement, endoscopy with intervention) within 4 weeks of first dose of study medications
Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 14 days prior to registration or those patients who receive a non-central nervous system (CNS) minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 3 days prior to registration; there is no waiting period for central line placement; there is a 7-day window for recovery prior to registration for patients who underwent stereotactic biopsy of the brain
Any surgery (not including minor diagnostic procedures such as lymph node biopsy) within 2 weeks of baseline disease assessments; or not fully recovered from any side effects of previous procedures; an interval of 1 week for stereotactic brain biopsy from the start of study treatment is acceptable
Nonstudy related surgical procedures prior to IP administration.
Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure; and no date of surgery (if applicable) or anticipated need for a major surgical procedure planned within the next 6 months (Note: The following are not considered to be major procedures and are permitted up to 7 days prior to study treatment: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures.)
Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc), celiac plexus block, and biliary stent placement
Patients who have had surgery within 4 weeks of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc), celiac plexus block, and biliary stent placement
Has undergone a surgical procedure involving general anesthesia within 2 weeks of starting trial treatment, or has inadequate healing or recovery from complications of surgery prior to starting trial treatment; this does not apply to low-risk procedures such as thoracentesis; paracentesis; chest tube/pleurX catheter placement; line placement; needle biopsy of tumor; and bronchoscopy
Non-study related surgical procedures less than or equal to 14 days prior to CK-101 administration
Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement
Major surgical procedures =< 28 days prior to D1 of AZD1775 or minor surgical procedures =< 7 days; no waiting required following port-a-cath placement
Patients who have had other surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement
Minor surgical intervention, including placement of a permanent catheter within 24 hours prior to the first infusion of bevacizumab
Major surgery (such as GI surgery) within 6 weeks of enrollment; however, subjects who have had a nephrectomy may be enrolled 4 weeks after surgery, providing there are no wound-healing complications; subjects with clinically relevant ongoing complications from prior surgery are not eligible; the following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
Have had had surgery within four weeks of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement
No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months; Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
Had surgery within 4 weeks prior to study treatment except for minor procedures (hepatic biliary stent placement is allowed)
All adverse events grade =< 2 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopecia or neuropathy; patients are eligible for enrollment if they have had no surgery in the prior 6 weeks (minor surgical procedures such as skin biopsies and port placement done on an outpatient basis do not require a waiting period)
Patients who have had surgery within 4 weeks of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc), celiac plexus block, and biliary stent placement
Have undergone major surgery within 28 days prior to first dose of AP32788. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed.
Major surgery (excluding placement of vascular access) ?21 days from beginning of the study drug or minor surgical procedures ?7 days. No waiting is required following implantable port and catheter placement.
Patients must be 4 weeks or greater, beyond major surgical procedures such as thoracotomy, laparotomy or joint replacement, and must be 1.5 weeks or greater, beyond minor surgical procedures such as biopsy of subcutaneous tumors, pleuroscopy, etc, and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery.
Patients having additional surgical procedures which may have affect recovery
Major surgical procedures =< 28 days of beginning AZD1775, or minor surgical procedures =< 7 days; no waiting period required following port-a-cath or other central venous access placement
Major surgical procedures =< 28 days of beginning study treatment, or minor surgical procedures =< 7 days. No waiting period required following port-a-cath placement.
Minor surgical procedures must be completed >= 7 days prior to randomization with documentation of adequate recovery from associated complications to grade =< 1; these include (but are not limited to) laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, endoscopic ultrasonography, skin biopsy, percutaneous needle biopsy, and routine dental procedures; as a precautionary measure, it is recommended, but not strictly required, that placement of a central venous access device, thoracentesis, or paracentesis be done 7 days before the initiation of protocol directed chemotherapy with documentation of adequate recovery from associated complications to grade =< 1
Major surgical procedures and open biopsies must be completed >= 28 days prior to randomization with documentation of adequate recovery from associated complications to grade =< 1
Patients who have had surgery within 4 weeks of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc), celiac plexus block, and biliary stent placement
Patients must have recovered from any surgical procedure before enrolling on this study:\r\n* Patients with a major surgical procedure within 28 days prior to enrollment should be excluded\r\n* Patients with an intermediate surgical procedure within 14 days prior to enrollment should be excluded\r\n* For minor surgical procedures (including Broviac line or infusaport placement), patients should not receive the first planned dose of bevacizumab until the wound is healed and at least 7 days have elapsed\r\n* There should be no anticipation of need for major surgical procedures during the course of the study\r\n** Examples of major, intermediate, or minor surgical procedures:\r\n*** Major procedures: Major craniotomy for tumor resection; organ resection; bowel wall anastomosis; arteriovenous grafts; exploratory laparotomy; thoracotomy\r\n*** Intermediate procedures: Ventriculoperitoneal (VP)-shunt placement; stereotactic brain biopsy\r\n*** Minor procedures: Incision and drainage of superficial skin abscesses; punch biopsy of skin lesions; superficial skin wound suturing; bone marrow aspirate and/or biopsy; fine needle aspirations; Broviac line or infusaport placement; paracentesis or thoracocentesis\r\n* Please note: Lumbar punctures or placement of peripherally inserted central catheter (PICC) lines are not considered minor procedures and may occur at any time prior to or during therapy
Major surgical procedures are not allowed ?28 days prior to FPA144 administration
Major surgical procedures within 14 days of administration of crenolanib (does not include line placement as needed for chemotherapy administration).
No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable). Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
At least 7 days since any minor surgery such as port placement
Had major surgery within 30 days of the first dose of study drug, minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.
No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable). Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
Major surgical procedures ?28 days, or minor procedures ?7 days.
Minor surgical procedures such as mediport placement or core biopsies within 7 days of study treatment
Major surgery (such as GI surgery) within 6 weeks of enrollment; however, subjects who have had a nephrectomy may be enrolled 4 weeks after surgery, providing there are no wound-healing complications; subjects with clinically relevant ongoing complications from prior surgery are not eligible; the following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
Patients may not have had major surgery or radiotherapy (therapeutic and/or palliative) within 14 days prior to initiation of study treatment, including CNS-directed radiation therapy; minor procedures, such as tumor biopsy, thoracentesis, or intravenous catheter placement are allowed with no waiting period
Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement
Major surgical procedures ?28 days of beginning study drug or minor surgical procedures ?7 days. No waiting is required following port-a-cath placement.
Patients who have had surgery within 4 weeks of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc), celiac plexus block, and biliary stent placement
Patients should have completed any major surgery >= 4 weeks prior to registration and must have completed any minor surgery >= 2 weeks prior to registration; patients must have fully recovered from the procedure\r\n* The following are examples of procedures considered to be minor: port placement, laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and dental extraction procedures\r\n* Insertion of a vascular access device, thoracentesis, paracentesis, and endoscopic ultrasonographic procedures are not considered to be major or minor surgeries
Recovery from any major or minor surgeries
Major surgery within 30 days prior to start of study drug; for patients who had port-a-cath placement, they should have the port-a-cath placement at least one week prior the initiation of leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX)
Major surgical procedures within 14 days of Day 1 administration of crenolanib.
Minor surgical procedures (needle/laparoscopic core biopsies) for limited purposes of tissue retrieval will be allowed; patients should not receive the first planned dose of bevacizumab until the wound is healed and 7 days have elapsed since the procedure
Minor surgical procedures such as placement of Port-a-Cath, stereotactic biopsy, fine needle aspirations, or core biopsies within 7 days prior to Day 1
Major surgery (not including minor diagnostic procedures such as lymph node biopsy) within 2 weeks of start of study drug; or not fully recovered from any side effects of previous procedures
Major surgical procedures =< 28 days before beginning study treatment or minor surgical procedures =< 7 day before beginning study treatment; no waiting required after placement of a vascular access device
Major surgical procedures ?28 days of beginning AZD1775, or minor surgical procedures ?7 days
Major surgery (with the exception of minor surgical procedures, such as catheter placement or tumor biopsy) within 28 days prior to the first dose of ponatinib
Major surgical procedures within 14 days of day 1 administration of crenolanib
Patients with the following invasive procedures:\r\n* Major surgical procedures, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 1 of therapy; central venous catheter placements are permitted to be completed 7 or more days prior to day 1 of therapy; however, peripherally inserted central catheter (peripherally inserted central catheter [PICC] or PIC line) may be placed at any time prior to or during therapy
Minor surgical procedures within 7 days prior to study enrollment
Minor procedures (such as a central line placement, needle biopsy, thoracentesis, or paracentesis) =< 3 days prior to registration
Have an understanding of study procedures
Have had had surgery within four weeks of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement
Patient must not require a minor surgical procedure (i.e., Broviac line or infusaport placement) =< 7 days prior to beginning therapy, and the wound must be healed prior to initiation of therapy
There should be no anticipation of need for major surgical procedures during the course of the study; examples include:\r\n* Major procedures:\r\n** Organ resection\r\n** Bowel wall anastomosis\r\n** Arteriovenous grafts\r\n** Exploratory laparotomy\r\n** Thoracotomy\r\n* Intermediate procedures: \r\n** Ventriculoperitoneal (VP)-shunt placement\r\n** Stereotactic brain biopsy\r\n** Paracentesis or thoracentesis\r\n* Minor procedures:\r\n** Incision and drainage of superficial skin abscesses\r\n** Punch biopsy of skin lesions\r\n** Superficial skin wound suturing\r\n** Bone marrow aspirate and/or biopsy\r\n** Fine needle aspirations\r\n** Broviac line or infusaport placement\r\n** Note: lumbar punctures or placement of peripherally inserted central catheter (PICC) lines are not considered minor procedures and may occur at any time prior to or during therapy
Major surgery within 4 weeks of study entry; minor surgical procedures (e.g. port insertion, pleurex catheter placement) are not excluded, but sufficient time should have passed for wound healing
Major surgical procedures =< 28 days of beginning study treatment, or minor surgical procedures =< 7 days (minor procedures done at time of laparoscopy are allowed); no waiting required following port-a-cath placement
